Sarah P. Shubeck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah P. Shubeck has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Justin B. Dimick
Department of Surgery, University of Michigan, Ann Arbor, MI
4 shared publicationsArielle E. Kanters
Department of Surgery, University of Michigan, Ann Arbor, MI
2 shared publicationsHari Nathan
Department of Surgery, University of Michigan, Ann Arbor, MI
2 shared publicationsJyothi R. Thumma
Department of Surgery, University of Michigan, Ann Arbor, MI
2 shared publicationsAva Ferguson Bryan
Department of Surgery, University of Chicago, Chicago, USA
1 shared publicationCaprice C. Greenberg
Department of Surgery, University of Wisconsin, Madison, WI
1 shared publication
Latest Publications
- Open Access
- 12 September 2026
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 18 (1) , 48
Immunotherapy for Triple-Negative Breast Cancer: Disparities in Access and Opportunities for Equity
Purpose of Review: This review examines disparities in the use of immunotherapy for triple-negative breast cancer (TNBC), with a focus on racial, ethnic and socioeconomic differences in access to treatment. We review the current immunotherapy landscape, various factors contributing to inequitable use and representation of minority populations in clinical trials. Recent Findings: Immunotherapy use for TNBC has increased rapidly, but disparities in receipt persist, particularly among patients with metastatic disease. Black, Hispanic, uninsured and socioeconomically disadvantaged patients are less likely to receive immunotherapy, while treatment at academic centers is associated with greater use. Inequities in biomarker testing and clinical trial access create additional barriers. Importantly, available evidence suggests comparable outcomes across racial and ethnic groups when immunotherapy is received. Summary: Current disparities in immunotherapy outcomes appear to be driven primarily by differences in access rather than treatment efficacy. Improving insurance coverage, biomarker testing, clinical trial representation and access to high quality cancer care will be critical as immunotherapy becomes increasingly integrated into TNBC treatment.
- 12 September 2026
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 18 (1) , 48
Open AccessImmunotherapy for Triple-Negative Breast Cancer: Disparities in Access and Opportunities for Equity
Purpose of Review: This review examines disparities in the use of immunotherapy for triple-negative breast cancer (TNBC), with a focus on racial, ethnic and socioeconomic differences in access to treatment. We review the current immunotherapy landscape, various factors contributing to inequitable use and representation of minority populations in clinical trials. Recent Findings: Immunotherapy use for TNBC has increased rapidly, but disparities in receipt persist, particularly among patients with metastatic disease. Black, Hispanic, uninsured and socioeconomically disadvantaged patients are less likely to receive immunotherapy, while treatment at academic centers is associated with greater use. Inequities in biomarker testing and clinical trial access create additional barriers. Importantly, available evidence suggests comparable outcomes across racial and ethnic groups when immunotherapy is received. Summary: Current disparities in immunotherapy outcomes appear to be driven primarily by differences in access rather than treatment efficacy. Improving insurance coverage, biomarker testing, clinical trial representation and access to high quality cancer care will be critical as immunotherapy becomes increasingly integrated into TNBC treatment.
- Open Access
- 23 May 2026
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 18 (1) , 30
Breast Conserving Therapy versus Mastectomy in Young Women: Oncologic and Quality of Life Outcomes
Purpose of Review: This review is intended to explore unique considerations for breast conservation versus mastectomy for management of unilateral breast cancer in young patients. Recent Findings: There is limited recent work directly comparing mastectomy and breast conserving therapy for young women. Historical work establishes oncologic equivalence of the two surgical approaches, and work within the last 10 years suggests minimal overall difference in quality of life. Summary: There are multiple patient specific factors, including patient preference and candidacy for adjuvant therapies, that can inform the best surgical management for those young patients diagnosed with unilateral breast cancer. Additionally, while the literature does not support one approach being definitively superior either in terms of oncologic benefit or quality of life, there are multiple patient-level factors that should be incorporated into an informed discussion with a young person diagnosed with breast cancer to help guide surgical treatment approach.
- 23 May 2026
- Published by Springer Nature in Current Breast Cancer Reports
- Vol. 18 (1) , 30
Open AccessBreast Conserving Therapy versus Mastectomy in Young Women: Oncologic and Quality of Life Outcomes
Purpose of Review: This review is intended to explore unique considerations for breast conservation versus mastectomy for management of unilateral breast cancer in young patients. Recent Findings: There is limited recent work directly comparing mastectomy and breast conserving therapy for young women. Historical work establishes oncologic equivalence of the two surgical approaches, and work within the last 10 years suggests minimal overall difference in quality of life. Summary: There are multiple patient specific factors, including patient preference and candidacy for adjuvant therapies, that can inform the best surgical management for those young patients diagnosed with unilateral breast cancer. Additionally, while the literature does not support one approach being definitively superior either in terms of oncologic benefit or quality of life, there are multiple patient-level factors that should be incorporated into an informed discussion with a young person diagnosed with breast cancer to help guide surgical treatment approach.
- 16 April 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 259, 116992
Understanding what surgical advanced practice providers want: A survey of autonomy, tasks, and training preferences across three institutions
- 16 April 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 259, 116992
Understanding what surgical advanced practice providers want: A survey of autonomy, tasks, and training preferences across three institutions
- Open Access
- 7 June 2025
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 6 (6) , e251467
Insurance Churn and the COVID-19 Pandemic
Importance: Many individuals in the US face a high risk of losing their health insurance coverage and experiencing insurance churn, especially those enrolled in Medicaid. Prior research has found that the risk of losing insurance coverage remains high in the US even after the Patient Protection and Affordable Care Act significantly reduced the number of uninsured individuals.Objective: To estimate whether the Families First Coronavirus Response Act (FFCRA) decreased insurance churn.Design, Setting, and Participants: This study used 2 quasi-experimental approaches: an interrupted time series approach and a difference-in-difference approach. Both approaches use individual-level data from the Medical Expenditure Panel Survey from January 2015 to December 2022. In the difference-in-difference analysis comparing individuals with Medicaid to individuals with private health insurance coverage, the probability that insured individuals aged 2 to 64 years lose insurance over the next 12 months before and after the FFCRA was estimated. Data were analyzed from January to November 2024.Main Outcomes and Measures: Primary outcome was the share of insured individuals who lost insurance coverage over the next 12 months. This measure was defined for all insured individuals and defined separately for individuals with Medicaid and for individuals with private insurance coverage.Results: The sample included 96 473 individuals. Of these, 46 779 (49.7%) were male, and the mean (SD) age was 31.9 (18.1) years. In the interrupted time series analysis, the FFCRA was associated with a reduction in insurance churn by 2.06 percentage points (β = −0.021; 95% CI, −0.024 to −0.018; P < .001). In the difference-in-difference analysis, the FFRCA reduced Medicaid churn by 5.51 percentage points (β = −0.055; 95% CI, −0.060 to −0.050; P < .001). Combining these estimates, 65.0% (95% CI, 54.8-75.3) of the reduction in insurance churn came from the reduction in Medicaid churn.Conclusions and Relevance: In this study, the FFCRA was associated with a significantly decreased risk of losing health insurance. Without the FFCRA, an estimated 2.94 million individuals with Medicaid would have lost insurance coverage each year during the COVID-19 public health emergency.
- 7 June 2025
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 6 (6) , e251467
Open AccessInsurance Churn and the COVID-19 Pandemic
Importance: Many individuals in the US face a high risk of losing their health insurance coverage and experiencing insurance churn, especially those enrolled in Medicaid. Prior research has found that the risk of losing insurance coverage remains high in the US even after the Patient Protection and Affordable Care Act significantly reduced the number of uninsured individuals.Objective: To estimate whether the Families First Coronavirus Response Act (FFCRA) decreased insurance churn.Design, Setting, and Participants: This study used 2 quasi-experimental approaches: an interrupted time series approach and a difference-in-difference approach. Both approaches use individual-level data from the Medical Expenditure Panel Survey from January 2015 to December 2022. In the difference-in-difference analysis comparing individuals with Medicaid to individuals with private health insurance coverage, the probability that insured individuals aged 2 to 64 years lose insurance over the next 12 months before and after the FFCRA was estimated. Data were analyzed from January to November 2024.Main Outcomes and Measures: Primary outcome was the share of insured individuals who lost insurance coverage over the next 12 months. This measure was defined for all insured individuals and defined separately for individuals with Medicaid and for individuals with private insurance coverage.Results: The sample included 96 473 individuals. Of these, 46 779 (49.7%) were male, and the mean (SD) age was 31.9 (18.1) years. In the interrupted time series analysis, the FFCRA was associated with a reduction in insurance churn by 2.06 percentage points (β = −0.021; 95% CI, −0.024 to −0.018; P < .001). In the difference-in-difference analysis, the FFRCA reduced Medicaid churn by 5.51 percentage points (β = −0.055; 95% CI, −0.060 to −0.050; P < .001). Combining these estimates, 65.0% (95% CI, 54.8-75.3) of the reduction in insurance churn came from the reduction in Medicaid churn.Conclusions and Relevance: In this study, the FFCRA was associated with a significantly decreased risk of losing health insurance. Without the FFCRA, an estimated 2.94 million individuals with Medicaid would have lost insurance coverage each year during the COVID-19 public health emergency.
- Open Access
- 19 March 2025
- Published by Springer Nature in Current Oncology Reports
- Vol. 27 (4) , 333-335
Young People with Cancer: A Growing Population in Need of United Attention
Each year, over 84,000 young people in the United States are diagnosed with cancer. These patients face unique burdens that defy historical “adolescent and young adult” and “early-onset cancer” silos. These groups share common vulnerabilities, including financial toxicity, disruptions to education and career development, and inadequate survivorship care. Research efforts to address these shared challenges remain inefficient due to parallel and uncoordinated investigations. Health policy decisions are similarly impacted, with the lack of a unified framework potentially leading to gaps in insurance coverage, disparities in resource allocation, and incomplete data collection on young people diagnosed with cancer. To address these challenges, a collaborative and integrated strategy across clinical care, research, and health policy is urgently needed. By unifying efforts and recognizing the shared experiences of young people with cancer, we can develop more effective support systems, optimize outcomes, and reduce the long-term burden of cancer for this fast-growing and vulnerable population.
- 19 March 2025
- Published by Springer Nature in Current Oncology Reports
- Vol. 27 (4) , 333-335
Open AccessYoung People with Cancer: A Growing Population in Need of United Attention
Each year, over 84,000 young people in the United States are diagnosed with cancer. These patients face unique burdens that defy historical “adolescent and young adult” and “early-onset cancer” silos. These groups share common vulnerabilities, including financial toxicity, disruptions to education and career development, and inadequate survivorship care. Research efforts to address these shared challenges remain inefficient due to parallel and uncoordinated investigations. Health policy decisions are similarly impacted, with the lack of a unified framework potentially leading to gaps in insurance coverage, disparities in resource allocation, and incomplete data collection on young people diagnosed with cancer. To address these challenges, a collaborative and integrated strategy across clinical care, research, and health policy is urgently needed. By unifying efforts and recognizing the shared experiences of young people with cancer, we can develop more effective support systems, optimize outcomes, and reduce the long-term burden of cancer for this fast-growing and vulnerable population.
- 26 January 2025
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 103, 233-247
Patient-reported upper extremity impairment following mastectomy with breast reconstruction: A systematic review
- 26 January 2025
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 103, 233-247
Patient-reported upper extremity impairment following mastectomy with breast reconstruction: A systematic review
- 18 November 2022
- Published by Elsevier in Surgical Clinics of North America
- Vol. 103 (1) , 83-92
De-Escalating Breast Cancer Therapy
- 18 November 2022
- Published by Elsevier in Surgical Clinics of North America
- Vol. 103 (1) , 83-92
De-Escalating Breast Cancer Therapy
- Open Access
- 23 February 2022
- Published by Springer Nature in npj Breast Cancer
- Vol. 8 (1) , 1-4
De-escalation in breast cancer surgery
In recent years, several trials of breast cancer treatment have failed to demonstrate a survival benefit for some previously routine surgical therapies in selected patient groups. As each of these therapeutic approaches has been deemed of low value deimplementation has varied significantly. This demonstrates that effective de-escalation in breast cancer surgery relies on more than the availability of data from randomized controlled trials and other high-quality evidence, but is also influenced by various stakeholders, social expectations, and environmental contexts.
- 23 February 2022
- Published by Springer Nature in npj Breast Cancer
- Vol. 8 (1) , 1-4
Open AccessDe-escalation in breast cancer surgery
In recent years, several trials of breast cancer treatment have failed to demonstrate a survival benefit for some previously routine surgical therapies in selected patient groups. As each of these therapeutic approaches has been deemed of low value deimplementation has varied significantly. This demonstrates that effective de-escalation in breast cancer surgery relies on more than the availability of data from randomized controlled trials and other high-quality evidence, but is also influenced by various stakeholders, social expectations, and environmental contexts.
- 1 March 2019
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 269 (3) , 453-458
Hot Spotting as a Strategy to Identify High-Cost Surgical Populations
Objective: The aim of this study was to determine the feasibility of “hot spotting” in elective surgical populations. Background: Prospective identification of high-cost patients, known as “hot spotting,” is well developed in medical populations, but has not been performed in surgical populations. Population-based management of surgical expenditures requires identification of high-cost surgical patients to allow for effective implementation of cost-saving strategies. Methods: Using 100% Medicare claims data for 2010 to 2013, we identified patients aged 65 to 99 years undergoing elective surgical procedures. We calculated price-standardized Medicare payments for the surgical episode from the index admission through 30 days after discharge. Patient-level factors associated with payments were analyzed by multivariable linear regression. Results: Medicare patients in the highest decile of spending accounted for a disproportionate share of aggregate costs: 30% in Colectomy (COL), 22% in coronary artery bypass grafting (CABG), 19% in Total Hip Arthroplasty, and 18% in Total Knee Arthroplasty. Medicare expenditure differences between the highest and lowest deciles were because of a 5-fold difference for COL and 3-fold difference for CABG in index hospitalization cost. In contrast, for orthopedic procedures, there were 47- to 80-fold post-acute care expenditures between highest and lowest deciles. In multivariable analyses, patients with ≥3 comorbidities had significantly higher costs than healthier patients. Conclusion: We found that a subset of multimorbid patients was responsible for a disproportionate share of total Medicare spending, but the individual components of spending vary by procedure. These findings suggest that targeting high-cost Medicare patients (ie, hot spotting) for cost containment efforts would be a potentially effective strategy to reduce costs in surgical populations.
- 1 March 2019
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 269 (3) , 453-458
Hot Spotting as a Strategy to Identify High-Cost Surgical Populations
Objective: The aim of this study was to determine the feasibility of “hot spotting” in elective surgical populations. Background: Prospective identification of high-cost patients, known as “hot spotting,” is well developed in medical populations, but has not been performed in surgical populations. Population-based management of surgical expenditures requires identification of high-cost surgical patients to allow for effective implementation of cost-saving strategies. Methods: Using 100% Medicare claims data for 2010 to 2013, we identified patients aged 65 to 99 years undergoing elective surgical procedures. We calculated price-standardized Medicare payments for the surgical episode from the index admission through 30 days after discharge. Patient-level factors associated with payments were analyzed by multivariable linear regression. Results: Medicare patients in the highest decile of spending accounted for a disproportionate share of aggregate costs: 30% in Colectomy (COL), 22% in coronary artery bypass grafting (CABG), 19% in Total Hip Arthroplasty, and 18% in Total Knee Arthroplasty. Medicare expenditure differences between the highest and lowest deciles were because of a 5-fold difference for COL and 3-fold difference for CABG in index hospitalization cost. In contrast, for orthopedic procedures, there were 47- to 80-fold post-acute care expenditures between highest and lowest deciles. In multivariable analyses, patients with ≥3 comorbidities had significantly higher costs than healthier patients. Conclusion: We found that a subset of multimorbid patients was responsible for a disproportionate share of total Medicare spending, but the individual components of spending vary by procedure. These findings suggest that targeting high-cost Medicare patients (ie, hot spotting) for cost containment efforts would be a potentially effective strategy to reduce costs in surgical populations.